Christopher Venner - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

All papers authored by Christopher Venner

Distributing this paper is prohibited by the publisher

2023 Jowon Laura Kim

ORCID

, Alina S. Gerrie

ORCID

, Kerry Joane Savage

ORCID

ORCID

ORCID

, Jeffrey W. Craig

ORCID

, Pedro Farinha

ORCID

, Brian Skinnider, Graham Slack, Joseph M. Connors

ORCID

, Laurie H. Sehn

ORCID

, Christopher Venner

ORCID

, Ciara L. Freeman

ORCID

Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis

Upload

This paper was not found in any repository, but could be made available legally by the author.

Richard LeBlanc

ORCID

ORCID

ORCID

ORCID

, Esther Masih‐Khan

ORCID

, Michael Chu, Victor Jimenez‐Zepeda

ORCID

, Michael Sebag, Kevin Song, Martha Louzada

ORCID

, Rami Kotb, Alissa Visram

ORCID

, Darrell White

ORCID

ORCID

, Antony Reiman

ORCID

and 5 other authors

Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis

Upload

This paper was not found in any repository, but could be made available legally by the author.

2021 Sosana Delimpasi

ORCID

, Maria Victoria Mateos, Holger W. Auner

ORCID

, Maria Gavriatopoulou

ORCID

, Meletios A. Dimopoulos

ORCID

, Hang Quach, Halyna Pylypenko, Roman Hájek, Xavier Leleu, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner

ORCID

, Reuben Benjamin

ORCID

, Mamta Krishnan Garg, Vadim Doronin and 9 other authors

Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

Upload

This paper was not found in any repository, but could be made available legally by the author.

Christopher P. Venner

ORCID

, Richard LeBlanc, Irwindeep Sandhu, Darrell White, Andrew R. Belch

ORCID

, Donna E. Reece, Christine Chen, Sean Dolan, Marc Lalancette, Martha Louzada, Andrea Kew, Arleigh McCurdy, Bethany Monteith, Tony Reiman, Gail McDonald and 4 other authors

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial

Upload

Missing publications? Search for publications with a matching author name.